All News

Article

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Jack Cush, MD Sep 12, 2025

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.

Article

SMART study - Single vs. Split Dose Methotrexate in RA

Jack Cush, MD Sep 11, 2025

Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.

Article

How to assess ILD in your patients?

Janet Pope, MD, MPH, FRCPC Sep 11, 2025

Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis.

Article

SLE and Osteoporosis

Sheila Reyes, MD Sep 11, 2025

In one of the SLE sessions at the APLAR 2025 Congress, Prof. Sandra Navarra discussed the assessment and management of osteoporosis in SLE patients, particularly glucocorticoid-induced osteoporosis (GIOP) and this article reviews the highlights and key takeaways from her talk.

In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality & SCD. ☝️these arrythmias present late so consider it in pts w/established dse who develop new-onset cardiac symptoms @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/MTDfxevqwb

https://x.com/RHEUMarampa/status/1964217545202016537/photo/1

2025 Update of EULAR RA management recommandation Summary slide inspired from Josef Smolen’s presentation @RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H

Is it #lupus? Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔 @RheumNow #APLAR25 https://t.co/xByBkjEr3r

Key takeaways of trabecular bone screening: 📌Complements but doesnt replace BMD/FRAX in fracture risk assessment 📌Dont exclude any lumbar spine unless w/significant change like laminectomy 📌Can use in monitoring untreated pts since TBS declines @RheumNow #APLAR25 https://t.co/bcN83IDDja

https://x.com/RHEUMarampa/status/1964182142780346407/photo/1

Remember! ☝️ Trabecular bone screening should not be routinely used in pre-menopausal women. @RheumNow #APLAR25 #osteoporosis https://t.co/hGMExyDYUX

https://x.com/RHEUMarampa/status/1964177254503895271/photo/1

Cross-sectional study of 320 dermatomyositis (198 classic DM, 122 amyopathic DM/CADM) & compared myositis panels for ANA, MSA, MAA, etc. Comparing CDM vs CADM - ANA pos in 63% vs 49%, p<0.05; MSA+ 47% vs 40% (NS); MAA+ 29% vs 26%(NS); MSA&MAA neg 40% vs 48% (NS)

Japanese retrospective real world study shows antifibrotic use assoc w/ better survival in Pulm Fibrosis-ILD for 1st 3 yrs & improved survival in progressive pulm. fibrosis (PPF) “despite management” (PPF subset prev Rx non-antifibrotic therapy) https://t.co/caiIuhg7j8 https://t.co/N0ST73TMoR

https://buff.ly/4nhpTUS

3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions, and potential new risks like dyspnea and pyrexia, not in the label. https://t.co/vP2YWGT2vR https://t.co/BruGBtXEBu

Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a…

Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses interstitial lung disease in Sjogren's disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/lA1vrBiar4

Single center study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Nearly half (49%) recv Rx for RA-ILD; few w/ TCZ, nintedanib, pirfenidone. ~90% had RA-ILD stability/improve @ 6 & 12 mos. Progression assoc w/ tobacco use (P .025) @ 6 mos https://t.co/AK4zYgcxeK

Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates on DMARDs treatment: global standards and regional adaptations" from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/zDo5NxKtbE https://t.co/kF9FxyWkIQ

Regional Disparities in DMARD Management for RA Treatment | RheumNow

Italian Systemic sclerosis (SPRING-SIR) registry - 1157/1538 (75%) SSc pts were in menopause, 632 (50%) had pre-menop SSc onset, 130 (14.4%) had early menopause. Post-menop. had more CREST, centromere Abs, ILD & GI Sxs. Pre-menop. had more diffuse Dz & peripheral vasculopathy. https://t.co/Jz2v5CkH0Y

ERS/EULAR guidelines for CTD-related interstitial lung disease The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have released clinical practice guidelines for evaluating and managing connective tissue diseases (CTD) https://t.co/2mmxsor4ND

COLCHICORT Trial The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors. https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR

COLCHICORT Trial | RheumNow

A new player in AIRD ThA age associated T helper cells Displaying both Cytotoxic & APC functions Correlation with disease activity in RA and SLE More research is needed to better characterize function but could be a promising therapeutic target @RheumNow #APLAR25 https://t.co/4SnY65tXpJ

https://x.com/AurelieRheumo/status/1964216189477093887/photo/1

What to give next? Bone sequencing therapy provides a novel perspective in #osteoporosis treatment. Several sequential approaches exist. Better treatment plan = better patient outcomes #APLAR25 @RheumNow @rheumarhyme https://t.co/XvwnT9ZCU2

Topics

All News

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

SMART study - Single vs. Split Dose Methotrexate in RA

How to assess ILD in your patients?

SLE and Osteoporosis

Do you get our email newsletter?